Convalescent plasma (CP) therapy
[대역어] None
[용어속성] Term
[용어속성] Term
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
Review
Published on
Journal: International immunopharmacology
[Category] COVID19(2023년), SARS, 변종, 임상, 치료제,
Journal: International immunopharmacology
[Category] COVID19(2023년), SARS, 변종, 임상, 치료제,
[키워드] 2019-nCoV, 2019 novel coronavirus
Abstract
accompany
ACE-2, Angiotensin-Converting Enzyme-2
acute respiratory disease syndrome
acute respiratory distress
acute respiratory syndrome
ADE, Antibody-dependent enhancement
adverse effect
AE(s), Adverse effect(s)
AEs
approach
ARDS
ARDS, acute respiratory distress syndrome
CAR, Chimeric antigen receptor
Cellular Immunotherapy
clinical trial
Community
complementary
Convalescent plasma (CP) therapy
coronavirus
COVID-19
COVID-19 vaccination
COVID-19 vaccines
COVID-19, Coronavirus disease 2019
CPT, Convalescent plasma therapy
CRP, C-reactive protein
CRS, Cytokine release syndrome
CT(s), Clinical trial(s)
Cytokine storm
Efficacy
effort
emerging disease
epidemiological
ESR, Erythrocyte sedimentation rate
FCR, Fc receptor
FDA, Food and Drug Administration
global pandemic
GM-CSF, granulocyte-macrophage colony-stimulating factor
group
GVHD, Graft-versus-host disease
HBV, Hepatitis B
HCV, Hepatitis C
highlight
HIV, Human immunodeficiency virus
HLH, Hemophagocytic lymphohistiocytosis
Human
I.V., Intravenous
IBD, Inflammatory bowel disease
IFN, interferon
IGG, immunoglobulin g
immunomodulation
Immunotherapy
Inflammation
inhibiting
International
investigated
IVIG, intravenous immunoglobulin
LAG-3, Lymphocyte-activation gene 3
LDH, lactate dehydrogenase
mAb(s), Monoclonal antibody(s)
MERS-COV, Middle East respiratory syndrome-corona virus
monoclonal antibody
MV, Mechanical ventilation
Passive
Passive immunotherapy
PCR, polymerase chain reaction
PD-1, Programmed cell death protein-1
platform
RA, Rheumatoid arthritis
RBD, receptor-binding domain
recent
reduced
SARS-CoV-2
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
syndrome
TIM-3, T cell immunoglobulin domain and mucin domain-3
TNF, Tumor Necrosis Factor
TRALI, Transfusion-related acute lung injury
treating COVID-19 patient
Treatment
Vaccine
variants of SARS-CoV-2
VEGF, Vascular endothelial growth factor
Viral load
viral neutralization
[DOI] 10.1016/j.intimp.2022.108786 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.intimp.2022.108786 PMC 바로가기 [Article Type] Review
Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis
Immunology
[키워드] 95% CI
all-cause mortality
anti-SARS-CoV-2 antibody
antibodies
assessment
baseline
baseline antibody status
Bia
Clinical improvement
Clinical outcome
Cochrane Library
convalescent plasma
Convalescent plasma (CP) therapy
coronavirus – COVID-19
Coronavirus disease 2019
Critically ill
development
discharge
Disease progression
disease severity
Efficacy
evaluate
Evidence
hyperimmune globulin
initial search
mechanical ventilation
Meta-analysis
Mortality
not differ
outcome
passive immunization
Patient
plasma
Randomized controlled trial
Registered
Registration
review
risk
SARS-CoV-2
searched
serotherapy
significantly
Standard of care
study population
subgroup
suggested
survival
systematic review
tested
Treatment
Trial
two groups
Web of Science
were used
[DOI] 10.3389/fimmu.2022.817829 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2022.817829 PMC 바로가기 [Article Type] Immunology